Anti-amyloid antibodies
Neurology· 2 reviewed drugs· 10695 cited findings behind them
What the regulatory reviews cover
Anti-amyloid antibodies reviewed in this library include Kisunla and Leqembi. Kisunla was reviewed for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild AD dementia due to Alzheimer’s disease (Early symptomatic Alzheimer’s disease) who are apolipoprotein E ε4 (ApoE ε4) non-carriers with confirmed amyloid pathology. Leqembi was reviewed for the treatment of Alzheimer’s disease, specifically for patients with mild cognitive impairment or mild dementia stage of disease.
Different drugs were studied in different trials, so figures are not head-to-head. For Kisunla, the iADRS slowing (donanemab vs placebo) was 32. Leqembi demonstrated a change from baseline in brain amyloid plaque (SUVR) of -0.310. The probability of Leqembi's 10 mg/kg biweekly regimen being superior to placebo by 25% (ADCOMS) was 64.
The drugs — one cited result each
| Kisunla Eli Lilly and Company | iADRS slowing (donanemab vs placebo): 32 Eli Lilly and Company — Kisunla EMA EPAR public assessment r, p.58 |
| Leqembi Eisai Co., Ltd. | Change from baseline in brain amyloid plaque (SUVR): -0.310 EISAI INC — Leqembi FDA Summary Review (NDA/BLA 761269, 2023, p.22 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Neurology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.